High-risk human papillomavirus (hrHPV) is the major cause of cervical cancer. The majority of hrHPV infections resolve spontaneously. However, when hrHPV escapes host’s immune system and establishes persistent infection in basal keratinocytes, self-clearance of the infection becomes exactly difficult, and medical intervention is urgently needed to eradicate viral infection and prevent cervical cancer. This review aimed to summarize our findings and achievements on REBACIN®—an anti-viral biologic with low cost, no cold chain and no hospitalization, and demonstrated that REBACIN® exhibits potent efficacy in clearing persistent hrHPV infections, promotes regression of associated lesions via targeted inhibition of viral E6/E7 oncogenes.